Moberg Pharma receives bondholders’ approval for increased flexibility in acquisition financing
STOCKHOLM, November 28th, 2016 - Moberg Pharma AB (OMX: MOB) has obtained a waiver from its bondholders to increase flexibility in acquisition financing. The waiver provides better possibility to optimize financing of acquisitions of profitable assets.Moberg Pharma’s outstanding senior unsecured floating rate bonds are due 2021, and encompass maximum SEK 600 million with a current outstanding amount of SEK 385 million (the “Bonds”). On November 8th, 2016 Moberg Pharma summoned a bondholders’ meeting, by way of a written procedure, to obtain a waiver from the holders of the Bonds (the “